globus medical, inc. is a leading musculoskeletal implant manufacturer and is driving significant technological advancements across a complete suite of spinal products. founded in 2003, globus’ single-minded focus on advancing spinal surgery has made it the fastest growing company in the history of orthopedics. globus is driven to utilize superior engineering and technology to achieve pain free, active lives for all patients with spinal disorders. additional information can be accessed at www.globusmedical.com.
Company profile
Ticker
GMED
Exchange
Website
CEO
David Demski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Globus Medical North America, Inc. • Branch Medical Group, LLC • Transplant Technologies of Texas, Ltd. • Human Biologics of Texas, Ltd. • Tissue Transplant Technology, Ltd. • Globus Medical India Private Limited • Globus Medical SARL • Globus Medical South Africa Pty Limited • Globus Medical Australia Pty Limited • Globus Medical UK Limited ...
IRS number
43744954
GMED stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
20 Feb 24
8-K
Globus Medical Reports Fourth Quarter and Full Year 2023 Results
20 Feb 24
8-K
Departure of Directors or Certain Officers
5 Feb 24
8-K
Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
10 Jan 24
S-8
Registration of securities for employees
30 Nov 23
8-K/A
Financial Statements and Exhibits
15 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Globus Medical Reports Third Quarter 2023 Results
7 Nov 23
8-K
Entry into a Material Definitive Agreement
2 Oct 23
8-K
Globus Medical Completes Merger with NuVasive
1 Sep 23
Transcripts
GMED
Earnings call transcript
2023 Q4
20 Feb 24
GMED
Earnings call transcript
2023 Q3
7 Nov 23
GMED
Earnings call transcript
2023 Q2
3 Aug 23
GMED
Earnings call transcript
2023 Q1
4 May 23
GMED
Earnings call transcript
2022 Q4
21 Feb 23
GMED
Earnings call transcript
2022 Q3
9 Nov 22
GMED
Earnings call transcript
2022 Q2
5 Aug 22
GMED
Earnings call transcript
2022 Q1
10 May 22
GMED
Earnings call transcript
2021 Q4
18 Feb 22
GMED
Earnings call transcript
2021 Q3
5 Nov 21
Latest ownership filings
4
Leslie V Norwalk
19 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Kelly Huller
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
SC 13G/A
Paul David C
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
4
Dan Wolterman
30 Jan 24
4
Leslie V Norwalk
30 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 279.62 mm | 279.62 mm | 279.62 mm | 279.62 mm | 279.62 mm | 279.62 mm |
Cash burn (monthly) | 8.94 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 61.29 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 218.33 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 24.4 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
80.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 422 |
Opened positions | 92 |
Closed positions | 45 |
Increased positions | 204 |
Reduced positions | 70 |
13F shares | Current |
---|---|
Total value | 5.37 tn |
Total shares | 108.38 mm |
Total puts | 98.68 k |
Total calls | 292.90 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 11.25 mm | $558.34 bn |
BLK Blackrock | 11.04 mm | $548.06 bn |
JHG Janus Henderson | 8.27 mm | $410.83 bn |
Nuance Investments | 3.62 mm | $179.76 bn |
STT State Street | 3.61 mm | $179.28 bn |
Wellington Management | 2.66 mm | $132.07 bn |
BK Bank Of New York Mellon | 2.41 mm | $119.49 bn |
William Blair Investment Management | 2.32 mm | $115.01 bn |
Hawk Ridge Capital Management | 2.23 mm | $110.51 bn |
JPM JPMorgan Chase & Co. | 2.13 mm | $105.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Norwalk Leslie V | Class A Common Stock | Sell | Dispose S | No | Yes | 51.99 | 10,590 | 550.57 k | 17,419 |
1 Mar 24 | Huller Kelly | Class A Common Stock | Sell | Dispose S | No | Yes | 54.53 | 3,115 | 169.86 k | 0 |
1 Mar 24 | Huller Kelly | Class A Common Stock | Sell | Dispose S | No | Yes | 53.79 | 4,385 | 235.87 k | 3,115 |
1 Mar 24 | Huller Kelly | Class A Common Stock | Option exercise | Acquire M | No | No | 24.9 | 7,500 | 186.75 k | 7,500 |
1 Mar 24 | Huller Kelly | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Option exercise | Dispose M | No | No | 24.9 | 7,500 | 186.75 k | 0 |
26 Jan 24 | David C Paul | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Grant | Acquire A | No | No | 53.75 | 75,000 | 4.03 mm | 75,000 |
26 Jan 24 | Scavilla Daniel T | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Grant | Acquire A | No | No | 53.75 | 140,000 | 7.53 mm | 140,000 |
26 Jan 24 | Keith W Pfeil | Stock Option (Right to Buy Class A Common Stock) Class A Common Stock | Grant | Acquire A | No | No | 53.75 | 60,000 | 3.23 mm | 60,000 |
News
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
4 Apr 24
The Latest Analyst Ratings For Globus Medical
18 Mar 24
Canaccord Genuity Reiterates Buy on Globus Medical, Maintains $79 Price Target
21 Feb 24
Key Takeaways From Globus Medical Analyst Ratings
21 Feb 24
Globus Medical Q4 2023 Adj EPS $0.60 Misses $0.61 Estimate, Sales $616.53M Beat $607.09M Estimate
20 Feb 24
Press releases
Globus Medical Schedules First Quarter Earnings Release and Conference Call
16 Apr 24
Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
13 Feb 24
CapitalGainsReport Sector Spotlight: Orthobiologics Watchlist (ORHB, ZBH, GMED, SYK)
9 Feb 24
Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer
5 Feb 24